Who We Are

We are drug hunters, protein engineers, and research scientists. Our teams work with partners to understand their broad program goals, develop full research plans, and carry out that research with the same dedication and commitment as would be carried out by their internal teams. Led by experienced biopharmaceutical leaders, Mosaic Biosciences' dedicated research teams rapidly advance protein therapeutics programs from concept to preclinical candidates. Mosaic is committed to changing how drug discovery is performed by providing this level of service and expertise.

Mosaic Biosciences' primary focus is discovering and validating protein and antibody therapeutics, however we have worked with a multitude of partners in differing and diverse areas, including nucleic acid-based therapeutics, target validation, and the development of protein and antibody-based tools. Not only are our team members talented and accomplished biologists, chemists, and engineers, but first and foremost they are critical thinkers, problem solvers, and dreamers. We love our work, and that passion translates to success for our partners!

Meet our team

Vision

To be the best therapeutic discovery service organization on the planet - eliminating the need for others to build or maintain internal discovery groups

Principles

Provide the highest level of expertise and service to our partners

Empower all employees to realize their full potential

Values

Be brave with our research

Have pride in our work

Respect one another

Have fun

Our partners

Start-up companies

looking to accelerate research by adding Mosaic's scientific leadership, tactical resources, or infrastructure.

Innovation or venture firms

seeking a fast way to validate innovative new ideas or incubate early therapeutics.

Biopharmaceutical companies

with a portfolio of ideas larger than their hired resources allow them to progress.

Development-stage biopharmaceutical companies

looking to add research capabilities.

Academic groups

looking to advance therapeutic programs to a state where they will command a higher valuation to support future investments.